Johnnie J. Orozco, Ph.D.
Affiliations: | 2004 | University of Washington, Seattle, Seattle, WA |
Area:
ImmunologyGoogle:
"Johnnie Orozco"Parents
Sign in to add mentor| Patrick S. Stayton | grad student | 2004 | University of Washington | |
| (Characterizing the humoral immune response to human papillomavirus type 6.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Orozco JJ, Vo PT, Gooley TA, et al. (2023) Targeted Radiation Delivery Before Haploidentical HCT for High-risk Leukemia or MDS Patients Yields Long-Term Survivors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Laszlo GS, Orozco JJ, Kehret AR, et al. (2022) Development of [At]astatine-based anti-CD123 radioimmunotherapy for acute leukemias and other CD123+ malignancies. Leukemia |
| Chow VA, Cassaday RD, Gooley TA, et al. (2021) Mega-dose 90Y-Ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. Blood Advances |
| Orozco JJ, Kenoyer AL, Lin Y, et al. (2020) Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and 90Y-DOTA. Molecular Cancer Therapeutics |
| Tuazon SA, Sandmaier BM, Gooley TA, et al. (2020) Y-labeled anti-CD45 antibody allogeneic hematopoietic cell transplantation for high-risk multiple myeloma. Bone Marrow Transplantation |
| Matesan MC, Fisher DR, Wong R, et al. (2020) Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry among Hematologic Malignancies. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine |
| Gyurkocza B, Nath R, Stiff PJ, et al. (2020) Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Allogeneic Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial Biology of Blood and Marrow Transplantation. 26 |
| Halpern AB, Howard NP, Othus M, et al. (2019) Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. Leukemia |
| Vo P, Gooley TA, Rajendran JG, et al. (2019) Yttrium-90-labeled anti-CD45 antibody followed by a reduced-intensity hematopoietic cell transplantation for patients with relapsed/refractory leukemia or myelodysplasia. Haematologica |
| O'Steen S, Comstock ML, Orozco JJ, et al. (2019) The Alpha Emitter Astatine-211 Targeted to CD38 can Eradicate Multiple Myeloma in a Disseminated Disease Model. Blood |